Tumour markers of prognosis in colorectal cancer by McLeod, H L & Murray, G I
Colorectal cancer is a common disease in developed nations. In
Europe, there are approximately 210 000 new cases per year and
around 124 500 people die from this disease each year (Parkin et
al, 1993). Thus, it is the second most common malignancy in men
and third most common in women. About one-third of patients
have a primary tumour in the rectum with the majority of the
remaining tumours occurring in the sigmoid colon. Patients who
die from the disease most commonly succumb to the effects of
secondary metastasis to the liver. The prognosis for this cancer is
influenced by a variety of features present at the time of initial
diagnosis. These factors include age, gender, duration of symp-
toms, presence of bowel obstruction, tumour location, need for
blood transfusion and the quality of surgical intervention
(Wolmark et al, 1983; McArdle and Hole 1991; Hermanek et al,
1995). A number of tumour characteristics, such as vascular and
lymphatic invasion, ploidy, differentiation and preoperative levels
of plasma carcinoembryonic antigen, have also been shown to be
of prognostic significance (Witzig et al, 1991; Hermanek et al,
1995). However, the simplest and most widely applied prognostic
feature is the presence of lymph node metastasis in a surgical
resection specimen. This forms the basis of all staging systems for
this disease and has repeatedly been shown to have more prog-
nostic power than any other single feature at presentation (Astler
and Coller, 1954; Cohen et al, 1991).
Treatment of colorectal cancer is unsuccessful if the tumours
have an aggressive phenotype at the time of diagnosis. To date, the
most important variable influencing the long-term outcome from
colorectal cancer is the stage of disease at diagnosis, with depth of
tumour invasion and infiltration of lymph nodes or distant organs
being used to define patient prognosis (Table 1). This classifica-
tion discriminates patients with early-stage disease from those
with very advanced disease, but is less able to predict the prog-
nosis of patients with intermediate levels of tumour invasion. For
example, in the Intergroup study of 929 patients with Dukes’ C
colorectal cancer, 45% of patients treated with surgery alone were
alive and disease free after 5 years compared with 65% of patients
treated with surgery followed by 5-fluorouracil(5-FU)/levamisole
(Moertel et al, 1995). This suggests that, in retrospect, nearly half
of the patients with Dukes’ C colorectal cancer did not require
adjuvant chemotherapy and 35% will die even when treated with
systemic chemotherapy. These data highlight the need for informa-
tive prognostic markers which will aid identification of patients
best treated with surgery alone, those requiring chemotherapy and
those who might benefit from more aggressive or experimental
therapy.
DEFINITION OF PROGNOSTIC MARKER
A practical definition of a prognostic marker is a variable that
provides prospective information on patient outcome which is
complementary to the data obtained by the pathologist from the
diagnostic sections and on which therapeutic decisions can be
guided. As Dukes’ staging is widespread and common practice,
there would be no logic in finding a marker that simply gave the
same information (Astler and Coller, 1954; Cohen et al, 1991).
Rather, proteins (or other variables) which demonstrate a strong
correlation with Dukes’ stage (or other staging systems) should be
considered as possible novel targets for anti-cancer therapies.
Dukes’ stage does provide a useful ‘internal control’, as it is the
gold standard on which prognostic markers should be compared,
and any study including Dukes’ A to D disease that does not
demonstrate a relationship between stage and survival should be
viewed with great suspicion.
A large number of prognostic markers for colorectal cancer are
featured in the medical literature. Almost all studies of prognostic
markers in colorectal cancer involve the correlation of variables
observed at diagnosis with eventual outcome. Most published
studies have used a single marker, while a minority of studies have
used a small group of prognostic markers from which clinical
correlations were derived. Although there are many claims of
prognostic significance in colorectal cancer the question remains:
which markers are important enough that they should be applied
prospectively in routine pathological evaluation of colorectal
cancer?
INCLUSION OF TREATMENT DATA
One difficulty with many prognostic marker studies is their applic-
ability to modern practice. A study demonstrating that overexpres-
sion of marker ‘X’ gives a survival advantage in patients with
Dukes’ stage C disease may have little relevance if the data are
derived from a population treated prior to the routine use of adju-
vant chemotherapy. This puts constraints on the length of clinical
follow-up information available, as chemotherapy only became
standard practice within the last 5–7 years in most centres. The
details of patient therapy are often inadequate in published studies
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Correspondence to: HL McLeodof prognostic markers. It is not satisfactory for the degree of hetero-
geneity of treatment regimens within a study to be greater than the
degree of tumour heterogeneity for the marker under evaluation.
CHOICE OF STUDY POPULATION
The choice of study population needs to be carefully considered for
studies of markers of potential prognostic importance. Many
published studies include patients with all Dukes’ stages (A to D),
which is useful for initial evaluation of putative markers of
prognosis. However, subsequent studies of patients with a specific
disease stage are then more appropriate for the assessment of the
clinical utility of a marker. For example, a study of 200 patients with
Dukes’ stage C disease will have greater statistical power to yield
definitive results than a study which consists of 20 Dukes’ A, 80
Dukes’ B, 80 Dukes’ C and 20 Dukes’ D patients. In addition to
diluting the statistical power of the study, the inclusion of all stages
of disease is inappropriate for the question asked, as there is little
potential for the clinical use of markers in stage A disease and
markers of tumour response to therapy or quality of life are more
applicable to stage D patients. The time scale in which the samples
are collected also has a significant influence on the applicability of
the results to modern cancer treatment. As mentioned above, the
treatment of colorectal cancer has changed significantly over the
past 10 years, and this changes the utility of prognostic findings.
Specialization of both surgeons and oncologists has improved
patient outcome (Hoffman et al, 1997). The technical ability of the
surgeon is also a relevant variable which should not be ignored in
studies of prognosis (Reinbach et al, 1994). The processing of
tumour specimens can alter the application of many techniques. For
example, the type of formalin and length of time in fixative can alter
the protein structure of target molecules, affecting the use of many
antibodies. These factors can also alter the integrity of genomic
DNA extracted from the tissue sections and thereby interfere with
microsatellite analysis or other DNA-based techniques. The devel-
opment of national guidelines for the processing of tumour samples
(such as the UKCCCR Handbook for the Clinico—Pathological
Assessment and Staging of Colorectal Cancer) should lead to a more
uniform handling of sample material.
THE ENRICHMENT APPROACH
It is not practicable to test all potential markers of prognosis in a
large data set of tumours of a particular Dukes’ stage. One poten-
tial strategy for providing initial data for putative prognostic
marker studies is the use of an ‘enrichment’ approach. With this
approach, a data set of patients could be retrospectively selected
based on their clinical phenotype, such as 5-year survival or
response to chemotherapy. By selecting patients at the extremes of
the desired endpoint (i.e. Dukes’ C patients alive 5 years post adju-
vant therapy vs patients who developed metastatic disease while
receiving adjuvant therapy) an ‘enrichment’ step should take
place. Variables only important for tumorigenesis should be
equally distributed between the two patient groups, while markers
of tumour invasion, chemosensitivity or other factors regulating
the efficacy of adjuvant therapy should be delineated between the
patient groups. This approach assumes a minimum degree of
heterogeneity in therapeutic regimens and can only be performed
using retrospective analysis. It also relies on the availability of
the relevant pathological specimens, often limiting laboratory
approaches to those that are applicable to formalin-fixed tissues.
There are, however, statistical concerns about the use of a large
number of potential tumour markers in what will often be a small
number of clinical specimens. However, the goal is to identify
markers with a clear association with outcome, and clinical signif-
icance needs to have a greater role than statistical significance. A
protein that is expressed in 30% of survivors and 0% of patients
with disease progression will be taken forward to more definitive
analysis, regardless of the statistics. This approach will not prove
the clinical utility of a marker, but rather should be a fertile ground
for identifying putative markers for further analysis in large
studies of specific tumour stage.
In this review, the current data on cellular or molecular markers
with the potential for prognostic predictive ability for patients with
colorectal cancer are summarized. It would not be possible to
explore all of the putative prognostic markers in the literature,
therefore those for which literature is available from either large
single studies or analysis from multiple laboratories were selected.
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Table 1 Comparison of the two most commonly used pathological staging
systems for colorectal cancer
Dukes’ stage AJCC/UICC
stage
Tumour invading the submucosa or muscularis A I
propria
Tumour invading through the muscularis propria B II
Evidence of tumour in regional lymph nodes, C III
regardless of local tumour invasion
Distant metastasis, regardless of local tumour Da IV
invasion or lymph node status
aStage D was not included in the original Dukes’ staging system, but has
become commonly used to represent distant metastasis.
Table 2 Comparison and applicability of different methodologies for assessment of tumour markers
PCR PCR SSCP LOH RT-PCR Northern blotting ISH IHC
Cellular constituent examined DNA DNA DNA mRNA mRNA DNA/mRNA Protein
Use in formalin-fixed, wax-embedded tissue Y Y Y N N Y Y
Microdissection needed Ya Ya Ya Ya Ya NN
Cellular localization evaluable N N N N N Y Y
Application to routine diagnosis Yb NN N N Y b Y
IHC, immunohistochemistry; ISH, in situ hybridization; LOH, loss of hetorozygosity; PCR, polymerase chain reaction; RT, reverse transcriptase, SSCP, single-
strand conformational polymorphism. aDepending on the cellularity of colorectal tumours, microdissection may be desirable to ensure an enriched population of
tumour cells. bAcademic centres and larger general hospitals.Papers were identified from the Institute for Scientific Information
database (through the Bath Information and Data Services) using
the search terms colon, rectal or colorectal with prognosis, prog-
nostic or survival. The search was conducted from January 1990 to
January 1998 and was restricted to English-language publications.
Negative studies may be under-represented in the literature
because of the personal and editorial bias against publishing such
work. The markers can be separated into oncogenes, tumour-
suppressor genes, proteins involved in apoptosis, factors involved
in angiogenesis/metastasis/invasion and cellular targets for the
chemotherapy used for colorectal cancer. An emphasis has been
placed on techniques that use immunohistochemistry, thereby
potentially enabling the results to be applied in many different
settings throughout the world. However, a spectrum of methodolo-
gies are available at most medical centres to assess tumour
markers (Table 2).
ONCOGENES
Ras
The  ras family represent one of the most commonly detected
oncogenes in human cancer. The ras genes (K-ras, H-ras, N-ras)
encode for 21-kDa proteins (p21s), which are localized on the
inner surface of the plasma membrane. These proteins bind
guanine nucleotides and have GTPase activity. As with other GTP-
binding proteins, ras may serve as a transducer molecule for
signals affecting cell proliferation and thus have involvement in
the cell cycle. The development of ras mutations is thought to be
an early event in the current model of colorectal tumorigenesis
(Fearon and Vogelstein, 1990). The prognostic significance of both
ras mutations and p21 staining has been assessed in a number of
reports, with conflicting results.
The majority of ras mutations are found in codon 12, with addi-
tional mutations observed in codons 13 and 61. Nested polymerase
chain reaction (PCR) methods for detection of ras mutations in
DNA isolated from formalin-fixed, paraffin-embedded colorectal
tumour have allowed assessment of prognostic significance using
retrospective analysis of large numbers of patients. Although there
are data in the literature on ras mutations and survival from over
1200 patients, the clinical relevance of these alterations is not yet
clear. At least four studies with a total of 498 patients demonstrate
that the presence of a ras mutation at either codon 12 or 13 is
associated with a poor prognosis, independent of Dukes’ stage
(Benhattar et al, 1993; Elnatan et al, 1996; Smith et al, 1996a;
Span et al, 1996). In addition, two studies with a total of 227
patients found a poorer prognosis in patients with mutations in
both ras and p53, even when either alteration alone was not an
independent predictor of survival (Bell et al, 1993; Smith et al,
1996a). A single study found that ras mutations were associated
with tumour progression and poor survival in patients with left-
sided tumours, but not in patients with right-sided disease (Elnatan
et al, 1996). There was no substantial difference in study design or
patient selection between the studies listed above and the seven
studies (a total of 610 patients) in which the presence of ras muta-
tions was not associated with prognosis (Dix et al, 1994; Bennett et
al, 1995; Markowitz et al, 1995; Elnatan et al, 1996; Pricolo et al,
1996; Andersen et al, 1997; Wadler et al, 1997). Most of the
studies in which no significance was identified had restricted
analysis to a specific pathological stage of disease [Dukes’ B
(Bennett et al, 1995); Dukes’ B/C (Dix et al, 1994); Stage III
(Pricolo et al, 1996); advanced disease (Wadler et al, 1997);
Markowitz et al, 1995], while the studies demonstrating a positive
correlation with prognosis included a mix of Dukes’ A–D
tumours. It is possible that the presence of ras mutations is associ-
ated with disease invasiveness, independent of pathological stage,
but is not of prognostic significance within a given stage of
disease. This may account, in part, for an association with survival
in the studies including Dukes’ A–D tumours and the lack of
prognostic importance in the studies including larger numbers of
patients with a specific pathological stage.
The influence of ras mutations on response to 5-FU-based
chemotherapy has been evaluated in 108 patients (Markowitz et al,
1995; Wadler et al, 1997). An objective response rate of 39% was
achieved with the different regimens, but mutant ras was not asso-
ciated with chemosensitivity.
Immunohistochemical analysis of ras p21 staining and outcome
has been performed in four studies (a total of 399 patients)
(Miyahara et al, 1991; Sun et al, 1991; Miller et al, 1992; Bennett
et al, 1995). Different monoclonal antibodies were used in all
studies and the method of scoring a tumour p21 as ‘positive’ either
was not detailed or differed between the studies. Tumour staining
for p21 was found in 54% (216/399) of tumours, but varied
between studies (31–71% positive). Positive staining for p21 was
associated with a poor prognosis in three out of four studies
(Miller et al, 1992; Sun et al, 1991; Miyahara et al, 1991) and was
shown to be an independent prognostic factor in only one study
(Sun et al, 1991). Although there are concerns about the method-
ology (non-specific ras antibody, criteria for ‘positive’ expression)
and statistical analyses used in these studies, there is an overall
indication that tumour staining for p21 is associated with a poor
prognosis and should be considered for inclusion in more defini-
tive studies of markers of prognostic significance in colorectal
cancer.
Transforming growth factor (TGF) a and b-1
The transforming growth factor (TGF) superfamily consists of
several subgroups, including a and b, of which there are a number
of isoforms (Kumar et al, 1995; Lawrence, 1996). TGF-a produces
a mitogenic effect through interaction with the epidermal growth
factor receptor and promotes the growth of colon cancer cells in
vitro in an autocrine manner. The role of TGF-a as a marker of
survival in colorectal cancer was evaluated in 105 patients (stage
not given) who were treated with surgery alone (Younes et al,
1996). Patients with low TGF-a expression (<25% positive cells)
had a poorer prognosis than those with >25% positive staining (P =
0.03). Although this brief report did not evaluate the independence
of TGF-a as a prognostic marker, the significant difference in
overall survival makes it a candidate for further evaluation.
TGF-b-1 is the most abundant member of the TGF-b family.
TGF-b-1 inhibits the growth of epithelial cells but stimulates
mesenchymal cell proliferation and cell migration. Resistance to
TGF-b-1-induced growth inhibition is observed in colorectal cancer
and is associated with tumour progression in laboratory models
(Robson et al, 1996). TGF-b-1 staining was evaluated in formalin-
fixed tissue from 72 patients with colorectal cancer (Dukes’ stage A,
5; B, 33; C, 16; D, 18) (Robson et al, 1996). Positive expression was
observed in 58% of tumours and was associated with Dukes’ classi-
fication (Dukes’ D, 72% vs Dukes’ A, 40%; P < 0.05). Poorer
survival was observed in patients with positive staining for TGF-
b-1. This was more apparent for patients receiving a palliative
Prognosis in colorectal cancer 193
British Journal of Cancer (1999) 79(2), 191–203 © Cancer Research Campaign 1999resection of their primary tumour than for patients receiving a cura-
tive resection (Robson et al, 1996). Unfortunately, evaluation of the
independence of TGF-b-1 staining from Dukes’ stage was not
reported in this study. However, the data suggest a role for TGF-b-1
staining in the context of advanced disease.
c-erbB2
The c-erbB2 proto-oncogene (also called Her-2, neu) is a 185-kDa
glycoprotein with tyrosine kinase activity. Expression of c-erbB2
has demonstrated prognostic significance in breast and gastric
cancer. However, it has not been extensively evaluated in
colorectal tumours. A study of 151 adenocarcinomas (Dukes’
stage A, 34; B, 40; C, 77) identified a significant relationship
between  c-erbB2 immunohistochemistry and patient survival
(Kapitanovic et al, 1997). c-erbB2 expression was found in all
cases and was strongly positive in 43% of tumours. An inverse
correlation between c-erbB2 staining and survival was noted, with
median survival of 120 weeks and 28 weeks for tumours with
moderate and strong staining for c-erbB2 respectively. Median
survival for patients with weak staining was greater than 275
weeks. Although c-erbB2 expression was significantly correlated
with Dukes’ stage, c-erbB2 was an independent marker of prog-
nosis in this study. c-erbB2 staining was also of prognostic impor-
tance in a study of 164 Dukes’ B tumours (Kay et al, 1994).
Cytoplasmic staining was observed in 33.5% of tumours and was a
poor prognostic indicator (5-year survival 47% compared with
77% in c-erbB2-negative tumours). c-erbB2 staining was also an
independent prognostic marker in 293 tumours (stage not stated)
(Sun et al, 1995). However, unlike the previous studies, a
favourable prognosis with overexpression was observed. This
finding was primarily confined to aneuploid tumours. This
discrepancy in the prognostic significance of c-erbB2 overexpres-
sion needs to be more definitively addressed before this marker
can be recommended for use in the management of patients with
colorectal cancer.
Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) is a 170-kDa transmem-
brane protein with tyrosine kinase activity. The receptor is able to
bind epidermal growth factor and to transduce the signal into the
cytoplasm. Expression of EGFR is of prognostic significance for a
number of solid tumours, including breast and ovarian carcinoma.
EGFR was evaluated in 82 patients with colorectal cancer (Dukes’
stage A, 4; B, 41; C, 22; D, 15; Mayer et al, 1993). Patients with
Dukes’ C disease received adjuvant 5-FU and levamisole, while
Dukes’ D patients received 5-FU and leucovorin. EGFR-positive
staining was detected in 80/82 (97.6%) colorectal tumours, with the
majority (62.2%) having >50% positive cells. Patients with >50%
positively staining cells had a poorer survival (median 22.5
months) than those with a lower degree of expression (>60 months;
P < 0.01) (Mayer et al, 1993). The role of EGFR as an independent
prognostic marker was not clearly defined, but Dukes’ stage and
lymph vessel invasion were also shown to be of prognostic impor-
tance. A second study evaluated EGFR in 84 patients with Dukes’
B colorectal carcinomas who had 10 years of follow-up informa-
tion (Linden et al, 1996). Although 52% of tumours expressed
EGFR, no association was found between EGFR and survival
(Linden et al, 1996). These two studies leave a great deal of uncer-
tainty regarding the role of EGFR in colorectal cancer. There is a
clear need for a further large study, preferably in patients with
Dukes’ B and C disease, to define the utility of EGFR immuno-
histochemistry as a marker of prognosis in colorectal cancer.
c-myc
Amplification of the cellular oncogene c-myc has been described
in both colorectal cell lines and primary tumours. c-myc gene copy
number was determined using a dot-blot technique in tumour
DNA from 149 patients with Dukes’ B or C colon cancer treated
on Intergroup study EST2284 (surgery vs surgery + levamisole vs
surgery + 5-FU + levamisole) (Augenlicht et al, 1997). Using an
arbitrary cut-off point of 1.5 to define amplification, 32% of
patients had elevated c-myc. Among patients with no c-myc ampli-
fication there was no difference in survival between the three treat-
ment arms. However, c-myc-positive patients treated with surgery
+ 5-FU + levamisole (n = 12) had a longer time to disease progres-
sion (P < 0.05) and a trend towards longer survival (P = 0.09) than
c-myc-positive patients treated with surgery alone (n = 25) or
surgery + levamisole (n = 11). While the small number of patients
with c-myc-positive tumours in each treatment group and the
failure to assess the independence of c-myc as a marker of prog-
nosis limit the interpretation of this study, it does suggest a role for
c-myc detection in the selection of patients with Dukes’ stage B or
C colon cancer for whom adjuvant chemotherapy is indicated.
RNA-based analysis of the prognostic impact of c-myc expres-
sion has also been performed in 119 patients (Dukes’ stage A, 31;
B, 27; C, 29; D, 32) and 29 patients (Dukes’ stage A, 2; B, 10; C,
10; D, 7) (Nagai et al, 1992; Smith and Goh, 1996). In addition,
analysis of c-myc DNA copy number was performed in the smaller
study (Nagai et al, 1992). Neither c-myc gene copy number nor
RNA expression was of prognostic significance in the smaller
study (Nagai et al, 1992). In contrast, c-myc overexpression was
observed in 60% of cases in the larger study and these patients had
a better prognosis than patients without overexpression (P = 0.02)
(Smith and Goh, 1996). However, the authors found that the
beneficial effect of c-myc overexpression was restricted to those
tumours containing wild-type p53 (Smith and Goh, 1996). This
highlights the fact that evaluation of a specific prognostic marker
cannot be carried out in isolation but needs to be studied in the
context of a more complex, multigenic environment.
Immunohistochemical analysis of c-myc protein in colorectal
tumours has been evaluated in two separate studies [n = 118,
Dukes’ A, 7; B, 35; C, 41; D, 35 (Miller et al, 1992) and n = 48,
Dukes’ B, 24; C, 24 (Bhatavdekar et al, 1997)]. Positive staining
for c-myc was found in 71% and 65% of patients, respectively, and
was not associated with Dukes’ stage or histological grade in
either study (Miller et al, 1992; Bhatavdekar et al, 1997). A signif-
icantly better overall survival was observed in the 17 patients
without c-myc staining, when compared with the 31 with positive
staining in the smaller study (Bhatavdekar et al, 1997). However,
c-myc was not of prognostic importance in the larger study (Miller
et al, 1992).
TUMOUR-SUPPRESSOR GENES
p53
The p53 tumour-suppressor gene is a commonly altered gene in
human solid tumours. The gene has been localized to chromosome
17p13.1, a region of allelic deletion in many tumours. The remaining
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Table 3 Molecular and cellular evaluation of p53 as a marker of prognosis in colorectal cancer. All immunohistochemistry (IHC) studies were performed on
formalin-fixed sections and the antibody used is listed in parenthesis. Studies evaluated nuclear staining for p53 unless otherwise indicated. The studies
presented here were selected from the literature based on large sample number or focus on a specific tumour stage
Technique Number of Significance Reference
tumours
Immunohistochemical analysis
IHC (DO-1) Dukes’ A = 42 Overexpression Bartik et al (1997)
Dukes’ B = 82 associated with poor
Dukes’ C = 84 survival in Dukes’
Dukes’ D = 45 B, but not Dukes’ A, C, D
IHC (DO-7) Dukes’ A = 54 Not an independent Kressner et al (1996)
Dukes’ B = 133 predictor of survival
Dukes’ C = 73
Dukes’ D = 34
IHC (CM-1) Dukes’ A = 43 Cytoplasmic, but not Sun et al (1992)
Dukes’ B = 101 nuclear, overexpression =
Dukes’ C = 94 poor survival
Dukes’ D = 50 Independent
IHC on endoscopic biopsies (1801) Dukes’ A = 25 Overexpression = Yamaguchi et al
Dukes’ B = 68 poor prognosis (1993)
Dukes’ C = 55 Independence not
Dukes’ D = 55 assessed
IHC (CM1) Stage I = 35 Cytoplasmic, but not Bosari et al (1994)
Stage II = 78 nuclear, overexpression =
Stage III = 70 poor survival
Stage IV = 23 Independent factor
IHC (DO-7) Stage I = 9 Not an independent Lanza et al (1996)
Stage II = 80 predictor of survival
Stage III = 69
Stage IV = 46
IHC (DO-7) and PCR–SSCP exons 5–8 Dukes’ A = 14 Overexpression = Leahy et al (1996)
Dukes’ B = 21 poor survival
Dukes’ C = 31 Independent factor
Mutation only
important for
Dukes’ A and B
(P = 0.01)
IHC (DO-1) Dukes’ A = 29 Not an independent Poller et al (1997)
Dukes’ B = 88 predictor of survival
Dukes’ C = 130
IHC (DO-7) and PCR + SSCP Dukes’ B = 263 Overexpression = Soong et al (1997)
exons 5–8 Dukes’ C = 278 good prognosis,
most significant for
distal tumours
Independent factor
IHC (DO-1) Stage IB = 53 Overexpression = Baretton et al (1996a)
Stage II = 48 poor survival
Independent factor
PCR-RFLP exon 4 plus IHC Dukes’ B = 168 Not associated with Bennett et al (1995)
(CM1) survival
IHC (1801) Dukes’ C = 107 Overexpression = Zeng et al (1994)
poor survival
Cytoplasmic p53 not
associated with
survival
IHC (1801) Dukes’ D = 50, Overexpression = Belluco et al
all treated with poor survival (1996)
intrahepatic
chemotherapy
IHC (DO-1) Dukes’ D = 59 Overexpression Brett et al (1996)
associated with
lower response
(P < 0.03), but not
survival
IHC (1801) Dukes’ D = 59 Overexpression not Costa et al (1997)
associated with
relapse or survival
IHC (1801) Dukes’ D = 71 Not associated with Paradiso et al
treated with response to therapy (1996)
5-FU modulated or survival
with methotrexateallele often contains an inactivating mutation. Wild-type p53 is
thought to be a stress response gene, the protein product of which
acts to maintain genetic integrity by inducing cell cycle arrest and
apoptosis following damage to the genome (Cox and Lane, 1995).
According to this model, inactivation of p53 function by allelic loss,
gene mutation or protein sequestration would be expected to lead to
increased genetic instability and to the survival of cells with damaged
DNA. Most studies of p53 protein in tumours have exploited the
observation that wild-type p53 has a short half-life and is usually not
detectable by immunohistochemistry, while missense gene mutations
are believed to extend greatly the half-life of the protein such that it
becomes detectable. Although there is a good correlation between the
presence of p53 gene mutations and positive p53 staining, discrepan-
cies do exist and can occur for a number of reasons, including lack of
protein from truncating mutations, overuse of ‘antigen retrieval’
methods and the criteria for classifying a tumour as ‘positive’ for p53
(reviewed in Wynford-Thomas, 1992; Baas et al, 1994; Hall and
Lane, 1994).
A large number of studies on the association between p53
immunohistochemistry or mutational analysis and survival have
been published, giving data for over 3000 patients. Immuno-
histochemical studies were performed using one of five different
monoclonal antibodies against p53, and the criteria for ‘positive’
staining varied from greater than 1% to more than 10% of tumour
nuclei. Several studies used two separate p53 antibodies and
inconsistencies between antibodies were noted for the same
tumour sections. Additional controversy also exists regarding the
localization of p53. Several studies have reported the presence of
cytoplasmic staining for p53, which they report to be of greater
prognostic significance than the more commonly observed nuclear
staining (Sun et al, 1992; Bosari et al, 1994). It is unclear whether
the cytoplasmic staining represents a methodological artifact or a
finding of biological and/or prognostic importance.
The wide availability of antibodies for immunohistochemistry of
p53 in formalin-fixed tissue has led to its use in the majority of
studies assessing the association between p53 and survival (Bosari
and Viale, 1995; reviewed in Manne et al, 1997). The role of p53
staining as a prognostic tool in colorectal cancer has been clouded by
a similar number of studies (and patient numbers) that have reported
poor survival in p53-positive cases as demonstrating no association
between p53 overexpression and outcome (Table 3). This conflict in
prognostic importance exists both in studies focusing on specific
stage of disease and in those including Dukes’ stage A–D. Although
the sample size of the majority of studies was 100–200 patients, the
presence of several larger studies (250–300) has not clarified the clin-
ical relevance of p53 immunohistochemistry.
Three out of four studies of p53 and survival in advanced
colorectal cancer found no association (Brett et al, 1996; Paradiso
et al, 1996; Costa et al, 1997), with the exception being an evalua-
tion of the impact in the context of intrahepatic chemotherapy for
liver metastasis (Belluco et al, 1996). A single study found no
association between either p53 staining or ras mutations and
survival, but identified a poor prognosis in patients whose tumour
contained both alterations (Bell et al, 1993). Additional studies
identified additive prognostic significance when p53 and bcl-2
alterations were present in the same patient (Barreton et al, 1996a;
Manne et al, 1997). This suggests the need for several large,
prospective studies (>500 patients) with long clinical follow-up
(>5 years) and a uniform treatment policy to provide definitive
data on the interplay between p53 and other putative prognostic
markers to identify patients with a poor prognosis for whom more
aggressive therapy may be appropriate.
Molecular analysis used either direct DNA or cDNA
sequencing or single-strand conformational polymorphism
(SSCP) and focused on p53 exons 5–8, where 98% of mutations
have been described. The concordance between immunohisto-
chemical and molecular analysis is 60–85%, with both false-posi-
tive and false-negative staining observed.
Studies of mutations in p53 have also been conflicting, with the
majority showing no association with patient survival (Goh et al,
1995; Leahy et al, 1996; Pricolo et al, 1996; Soong et al, 1997)
(Table 3). The studies showing no association had longer patient
follow-up, suggesting that the effort of tumour microdissection and
the time and expense of p53 sequencing or SSCP is not a worth-
while exercise for identifying patients at risk of poor survival.
The largest study of p53 alterations and patient prognosis (541
patients) used both immunohistochemistry and PCR-SSCP and
had a mean patient follow-up time of over 7 years (Soong et al,
1997). Although no association with prognosis was identified
from the molecular analysis, an improved survival was found in
patients with an overaccumulation of p53. This puzzling finding
was strongest for distal colonic tumours and patients with Dukes’
C disease. However, even in the left-sided tumours, the improve-
ment in patient survival associated with p53 staining was 10–20%.
This smaller degree of survival advantage may help to explain
why many smaller studies of mixed tumour stages have found no
statistically significant prognostic importance for p53. Only a
small number of patients in the study received post-operative
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Molecular analysis
RT-PCR-SSCP Dukes’ A–D, Mutation = poor Goh et al (1995)
n = 192 survival
Independent of stage
(P = 0.031)
IHC (DO-7) and PCR–SSCP Dukes’ A = 14 Mutation = poor Leahy et al (1996)
exons 5–8 Dukes’ B = 21 survival for Dukes’
Dukes’ C = 31 A and B
PCR–RFLP exon 4 plus IHC Dukes’ B = 168 Not associated with Bennett et al (1995)
(CM1) survival
IHC (DO-7) and PCR + SSCP Dukes’ B = 263 Not associated with Soong et al (1997)
exons 5–8 Dukes’ C = 278 survival
Table 3 Cont
Technique Number of Significance Reference
tumourschemotherapy, restricting the application of these data to current
treatment protocols.
Studies in cell lines with a homozygous mutant p53 genotype
demonstrated a high degree of resistance to radiation and several
chemotherapy agents, including 5-FU (Lowe et al, 1993). This
provided the basis for four studies (a total of 222 patients) of the
association between p53 staining and response to either systemic
or intrahepatic 5-FU-based chemotherapy for advanced colorectal
cancer (Belluco et al, 1996; Brett et al, 1996; Paradiso et al, 1996)
or combined chemoradiation neoadjuvant therapy in rectal cancer
(Spitz et al, 1997). Immunohistochemistry was performed in
formalin-fixed tissues using either monoclonal antibody 1801
(Belluco et al, 1996; Paradiso et al, 1996) or DO-1 (Brett et al,
1996; Spitz et al, 1997) and the criteria for a p53-positive tumour
ranged from greater than 1% to greater than 10% of tumour nuclei.
Tumour staining for p53 was not associated with response to either
biochemically modulated (with methotrexate) or intrahepatic 5-FU
therapy (Belluco et al, 1996; Paradiso et al, 1996), but a poorer
response rate to 5-FU and folinic acid was observed in patients
with p53 overexpression (Brett et al, 1996). Positive p53 staining
in pretherapy biopsy samples was inversely correlated with a
complete pathological response to chemoradiation therapy and
directly correlated with an increased likelihood of residual tumour
in the lymph nodes of surgical specimens (Spitz et al, 1997). This
suggests that p53 staining may be a tool for identifying patients
who will benefit most from neoadjuvant chemoradiation therapy
or those for whom more aggressive therapy is required.
Deleted in colon cancer/allelic variance at 18q
The deleted in colon cancer (DCC) gene, which is found on chro-
mosome 18q21.2, is a putative tumour-suppressor gene with impli-
cations for tumour progression and prognosis in colorectal cancer.
An important step in the Vogelstein and Fearon model of colon
tumorigenesis is loss of parts of chromosome 18q, including the
region containing DCC (Fearon and Vogelstein, 1990). Although
there is conflicting information on the role of the DCC protein in
tumour biology, there is evidence that it is of prognostic impor-
tance in colorectal cancer. The observed allelic loss of chromo-
some 18q has been linked to the prognosis of patients with stage II
colorectal cancer (Jen et al, 1994). Analysis of normal and tumour
DNA from microdissection of formalin-fixed, paraffin-embedded
sections was performed using the dinucleotide microsatellite
markers D18S58 and D18S61. No difference in prognosis was
observed between patients with stage III disease and 18q loss (n =
54) when compared with those with no allelic loss (n = 16).
However, among patients with stage II disease, the 5-year survival
was 93% for those with no 18q loss (n = 29) compared with 54%
for those with allelic loss (n = 36, P = 0.006). The survival rate for
stage II patients with 18q loss was not statistically different from
that of patients with stage III disease. In multiple regression
proportional hazards models, 18q was an independent prognostic
marker and 18q loss gave a 2.5 to 3.0-fold higher risk of death. The
prognostic importance of 18q allelic loss was verified in a study of
126 patients (stage I, 32; II, 50; III, 44), using four microsatellite
markers on microdissected tumour (Ogunbiyi et al, 1998). Loss of
18q was an independent marker of poor prognosis, with a 1.65
relative risk of disease-free survival. Loss of 18q was prognosti-
cally important in both stage II and III disease. A poor prognosis in
patients with loss of a polymorphic allele in DCC was also
observed among 95 patients with colorectal cancer (Dukes’ A, 10;
B, 23; C, 47; D, 15), in which normal and tumour DNA was
analysed by restriction fraction length polymorphism (RFLP)
(Ishimaru et al, 1994). Loss of heterozygosity (LOH) at DCC gave
a 5.5-fold higher risk of death and was an independent marker of
survival. However, Dukes’ stage was not an independent prog-
nostic marker in the multivariate analysis.
Not all studies of 18q have demonstrated a prognostic influence.
Analysis of normal and tumour DNA from 100 colorectal tumours
(Dukes’ B, 56; Dukes’ C, 44) using RFLP found no relationship
between LOH at DCC and survival (Dix et al, 1994). The median
clinical follow-up was 18.9 months in the Dix et al (1994) study,
compared with 35.4 months in the study by Jen et al (1994), and
may be a reason for the discrepancy in results for this marker in
patients with Dukes’ B and C disease. The influence of 18q loss on
prognosis has also been evaluated in metastatic colorectal cancer
(Kochhar et al, 1997). LOH on 18q (microsatellite markers D18S34,
D18S49, D18S35, D18S58, D18S61) was assessed in 141 patients
undergoing potentially curative liver resection for colorectal cancer.
The majority of tumours were non-informative for 18q markers but
were informative for other loci, limiting the interpretation of this
study. Among the informative cases for 18q, no relationship with
either survival or disease-free survival was observed.
The use of DNA-based assessment of 18q or DCC is cumbersome
and requires facilities for both high-quality microdissection and
quality-controlled molecular biology, and therefore is unlikely to
provide an approach that will have broad application to the planning
of colorectal cancer treatment. There has been one published study
of the prognostic implications of DCC protein staining (Shibata et
al, 1996). Using a polyclonal antibody (antibody 721) and a
microwave antigen retrieval protocol on formalin-fixed, paraffin-
embedded tissue sections, DCC staining was evaluated in 132
patients with colorectal cancer (stage II, 70; stage III, 62) and a
median follow-up of 92 months. Immunohistochemistry revealed a
granular cytoplasmic staining pattern for DCC and was scored as the
presence of any immunoreactivity or no evidence of staining. The
expression of DCC was a prognostic factor for survival in both stage
II and stage III disease. In patients with stage II disease, the 5-year
survival in patients with DCC staining was 94.3% compared with
61.6% in DCC-negative tumours (P < 0.001). In stage III disease,
the 5-year survival was 59.3% with DCC staining compared with
33.2% in DCC-negative tumours. Expression of DCC was an inde-
pendent prognostic factor which gave a threefold relative risk of
death. Only tumour staging gave a similar level of prognostic infor-
mation. The ease of immunohistochemical assessment of DCC will
allow additional large prognostic studies to determine the role of
DCC expression in the treatment planning for colorectal cancer.
p27
The expanding understanding of cell cycle regulation has identified
putative oncogenes and tumour-suppressor genes that may be
involved in colorectal tumorigenesis. However, there have been
few evaluations of the prognostic implications of alterations in cell
cycle proteins. The cell cycle inhibitor p27 (also known as Kip 1) is
a putative tumour-suppressor gene, but inactivating mutations have
not been described in human tumours. Immunohistochemical
analysis of p27 in formalin-fixed, paraffin-embedded sections
detected variable expression in the cytoplasm, nucleus, or both, in
90% of colorectal tumours, when using a microwave-based method
(Loda et al, 1997). Scoring of p27 staining was expressed as a ratio
of positive cells to total number counted and all immunoreactive
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p27 staining and prognosis was observed among 149 patients with
colorectal adenocarcinoma (stage I, 31; II, 66; III, 51; IV, 1), when
median survival was 151 months in patients with p27-positive
tumours (n = 134) and 69 months in patients with p27-negative
tumours (n = 15). Both tumour stage and grade showed a signifi-
cant association with survival. The prognostic significance of p27
staining was independent of tumour stage and grade (P = 0.003).
The effect of p27 was observed when analysis was confined to
patients with stage II disease, with absence of staining giving a 2.9
relative risk of death from colorectal cancer. These encouraging
data now needs confirmation in a larger independent data set
containing patients with uniform treatment before widespread use
of p27 as a prognostic marker can be recommended.
Allelic loss/genome damage
Although allelic instability is a common event in colorectal cancer,
the prognostic impact of instability has not been extensively eval-
uated. Seventy-five patients (stage not reported) were evaluated
for the impact of allelic deletion in chromosomes 5q and 17p on
survival, using Southern blot analysis (Khine et al, 1995). Loss of
chromosome 5q was observed in 32% of cases and 17p loss was
found in 69%, with loss of both regions in 27% of patients and
neither region in 25%. Poorer survival in patients with loss of
chromosome 5q was apparent (P = 0.014). Although patients with
17p allelic deletion had a poorer survival, this did not reach
statistical significance (P = 0.16). Multivariate analysis identified
Dukes’ stage and allelic loss of chromosome 5q as the two inde-
pendent markers of survival (P = 0.0001). An additional study
evaluated allelic loss on chromosome 1p in 116 colorectal
tumours, of which 82 (stage I, 17; II, 36; III, 29) were informative
and evaluable for survival analysis (Ogunbiyi et al, 1997). Loss of
1p was detected in 22/82 tumours and was associated with a
poorer disease-free survival. Loss of 1p was a weak but statisti-
cally significant independent marker of survival in multivariate
analysis. Although the methodology used in these studies is too
cumbersome for widespread application, the availability of
microsatellite markers of regions throughout the genome may
facilitate further evaluation of this approach for identifying
patients at risk for poor long-term survival.
Genomic DNA fingerprinting has recently been used to assess
the prognostic implications of tumour genome instability (Arribas
et al, 1997). By comparing banding patterns from arbitrarily
primed PCR analysis of 63 colorectal tumours and adjacent
normal tissue, an index of genomic instability was derived and was
an independent marker of prognosis. This technique does not
identify specific target genes for development as markers or
cellular targets for chemotherapy, but does provide an apparently
reproducible method for detection of genome-wide instability for
high-throughput prognostic studies. The small number of patients
at each disease stage limits the conclusions from the initial study,
but does provide the basis for further analysis of this methodology
as a potential marker of patient survival.
APOPTOSIS PATHWAYS
bcl-2
The  bcl-2 proto-oncogene encodes a 25-kDa protein that is
involved in the regulation of cell death by inhibiting apoptosis
through mechanisms which are not yet defined. Its overexpression
provides a growth advantage to tumour cells in vitro by blocking
apoptosis. However, evaluation of bcl-2 protein expression in
lung, thyroid and breast carcinomas identified a favourable prog-
nosis in patients with overexpression of bcl-2 on tumour staining.
The association between bcl-2 immunohistochemistry and patient
survival has been evaluated in at least six studies of colorectal
tumours (a total of 932 patients) (Bosari et al, 1995; Ofner et al,
1995; Sinicrope et al, 1995; Baretton et al, 1996b; Manne et al,
1997; Schneider et al, 1997). The larger studies (n = 205 and 231)
combined Dukes’ stages A–D and found no association between
bcl-2 overexpression and relapse or survival (Bosari et al, 1995;
Schneider et al, 1997). In addition, bcl-2 staining was not associ-
ated with response to 5-FU-based chemotherapy (Schneider et al,
1997). Bcl-2-positive tumours were associated with a better prog-
nosis in the remaining studies, although not always as an indepen-
dent marker of overall survival (Ofner et al, 1995; Sinicrope et al,
1995; Baretton et al, 1996b; Manne et al, 1997). An interaction
between bcl-2 overexpression and p53 staining was identified in
several studies, with bcl-2-positive/p53-negative tumours being
associated with a better survival than tumours with other staining
patterns (Baretton et al, 1996b; Manne et al, 1997). This supports
the need for studies of the interplay between bcl-2 and other puta-
tive prognostic markers to identify patients with a poor prognosis
for whom alternative therapy may be appropriate.
bcl-2 does not act alone but forms heterodimers with other
family members, including BAX, to regulate apoptosis in in vitro
systems. However, there are no data on the association between
BAX staining and prognosis in colorectal cancer. The recent
development of techniques for the use of BAX antibodies in
formalin-fixed, paraffin-embedded tumour tissue should allow this
marker to be assessed in the near future (Apolinario et al, 1997;
Koshida et al, 1997).
CELL PROLIFERATION
Cell proliferation has been extensively studied using a variety of
direct and surrogate markers. Currently one of the most popular
methods of assessing cell proliferation is using antibodies that
recognize nuclear proteins involved in, or altered during, the cell
cycle. One of the most frequently studied targets is proliferating
cell nuclear antigen (PCNA). This is a DNA polymerase d acces-
sory protein which can complex with cyclin D and cyclin-depen-
dent kinases (i.e. p21). Ki-67 is another frequently used antibody,
detecting an antigen expressed in all phases of the cell cycle
except G0. Evaluation of PCNA in 79 colorectal tumours (Dukes’
A, 4; B, 48; C, 27) by immunohistochemistry was performed with
follow-up for a minimum of 10 years (Neoptolemos et al, 1995). A
PCNA score was derived by a relatively complex, subjective four-
point scale according to the percentage of positive tumour cells.
The PCNA index was not associated with patient survival. Sun et
al (1996) studied PCNA in a series of 293 colorectal carcinomas
(Dukes’ A, 43; B, 101; C, 94; D, 50; stage not available for 5)
which had been collected over a 15-year period and followed up
for a minimum of 5 years. PCNA was assessed by counting 500
tumour nuclei and the final PCNA score was divided into four
groups according to the percentage of positive nuclei. PCNA did
not correlate with survival. This group also studied PCNA expres-
sion in 56 primary tumours and their corresponding lymph node
metastases with good correlation between the tissues. PCNA
expression was investigated in 71 advanced colorectal cancers
(metastatic,  n = 33, or recurrent disease, n = 38) eligible to receive
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analysing 1000 nuclei, and a ‘high’ PCNA score (greater than 32%
positive cells) was associated with improved survival and was
independently prognostic.
ANGIOGENESIS/METASTASIS/INVASION
Thymidine phosphorylase
Thymidine phosphorylase, or platelet-derived endothelial cell
growth factor, is an enzyme that catalyses the reversible phos-
phorylysis of thymidine and deoxyuridine to their bases and de-
oxyribose phosphate. It has been shown to be capable of inducing
angiogenesis, and expression of thymidine phosphorylase may
also be important for the activation of certain prodrugs, for
example deoxyfluorouridine conversion to fluorouracil (Griffiths
and Stratford, 1997). Thymidine phosphorylase was evaluated in
93 colorectal cancers (Dukes’ stage A, 30; B, 42; C, 21) by
immunohistochemistry using a monoclonal antibody (Takebayashi
et al, 1996). The immunohistochemical assessment used was a
straightforward two-point scale, with tumour being classified as
positive if more than 5% of tumour cells displayed staining.
Normal colon mucosa did not stain, whereas staining was
observed in both tumour and stromal cells. No comment was made
regarding the significance of stromal cell staining in the absence of
tumour cell staining or how this was scored. The presence of
thymidine phosphorylase was associated with a significantly
poorer prognosis. Although expression correlated with other
histopathological criteria (lymph node metastasis, lymphatic and
venous invasion), thymidine phosphorylase also appeared to be an
independent prognostic factor.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a glycoprotein that
shares some homology with platelet-derived growth factor and is
intimately involved in promoting angiogenesis. Interest in angio-
genesis has grown because of the possibility of using anti-angio-
genic therapy to prevent tumour progression. There have been
several recent reports of the analysis of VEGF in colorectal cancer,
all of which used immunohistochemistry on formalin-fixed, wax-
embedded sections and showed that VEGF is primarily localized
to tumour cells. In the largest study of 175 colorectal carcinomas
(stage 0, 7; I, 24; II, 48; III, 59; IV, 37), the presence of VEGF
correlated with increasing tumour stage and was associated with
decreased overall survival (P < 0.05) and decreased disease-free
survival (P < 0.01) (Kang et al, 1997). However, it was not an
independent prognostic factor. Amaya et al (1997) studied the
presence of VEGF in 133 cases of colorectal cancer (stage I, 14; II,
42; III, 45; IV, 29 with three unclassified cases). VEGF was local-
ized to tumour cells, and VEGF-positive tumours had a signifi-
cantly poorer prognosis than VEGF-negative tumours (P < 0.02),
which remained significant in a multivariate analysis. A much
smaller study of VEGF in 27 Dukes’ stage B patients showed
essentially similar results (Takahashi et al, 1997).
Matrix metalloproteinases and inhibitors
The matrix metalloproteinases (MMPs) are a group of enzymes
with a central role in matrix degradation, and there is considerable
evidence to indicate that this group of enzymes have a key role in
tumour invasion and metastasis. The current concept of the MMPs
in tumour invasion is that they not only have a direct role in facili-
tating extracellular matrix degradation but as a consequence they
also have an important role maintaining the tumour environment
and thus promoting tumour growth (Chambers and Matrisian,
1997). There are currently at least 15 known MMPs, which are
broadly classified into collagenases, gelatinases, stromelysins
and membrane-type MMPs. The MMPs (except membrane-type
MMPs) are produced as proenzymes and are activated by cleavage
of N-terminal propeptides. Our group identified MMP-1 (intersti-
tial collagenase) in 64 patients with colorectal cancers (Dukes’ A,
1; B, 38; C, 25). The presence of MMP-1 in tumour cells was asso-
ciated with poorer prognosis and was independent of Dukes’ stage
(Murray et al, 1996). This study used a simple assessment of the
presence or absence of MMP-1 immunoreactivity and is likely to
be more reproducible than some of the more complex scoring
schemes used in other immunohistochemistry studies. MMP-9
mRNA has been identified by in situ hybridization and Northern
blotting in 71 tumours (Dukes’ A, 11; B, 18; C, 16; D, 26), and a
high ratio of tumour to normal MMP-9 mRNA was associated
with poor prognosis and was independent of Dukes’ stage (Zeng et
al, 1996). In a small group (n = 31) of colorectal cancers, total type
IV collagenase activity (MMP-2 and MMP-9) has been found to
be prognostically significant, with high activity associated with
both shorter disease-free survival and shorter overall survival
(Ambiru et al, 1997). These findings of the different MMPs
emphasize the need to perform a comprehensive series of studies
of MMPs in colorectal cancer to understand the interactions
between the individual MMPs and to identify which of the MMPs
are most appropriate as prognostic markers. Studies are also
required to determine whether it is more relevant to assess total
enzyme or active enzyme. Clinical trials of MMP inhibitors are
now under way and require evaluation in relation to tumour MMP
expression to determine if MMP expression is a reliable method of
selecting patients for anti-MMP therapy. The MMPs are inhibited
in vivo by naturally occurring inhibitors, tissue inhibitors of
metalloproteinases (TIMPs). There are currently four known
TIMPs, and studies are also necessary to determine the contribu-
tion of TIMPs to prognosis.
Urokinase-type plasminogen activator and inhibitor
Urokinase-type plasminogen activator (uPA) is a serine protease
which catalyses the activation of plasminogen to plasmin, a broad-
spectrum protease which in turn can break down a variety of extra-
cellular matrix components and also promote the activation of
MMP-2. In a series of Dukes’ B colon cancers (n = 70), a higher
proportion of uPA-positive tumour cells by immunohistochemistry
was associated with poorer survival (P = 0.01) (Mucalhy et al,
1994). However, most tumours had a high percentage of positive
tumour cells (57/70) and only 13 cases had a low percentage of
positive tumour cells. In addition, stromal staining for uPA showed
an association with survival. This study is one of relatively few to
study a marker in relation to a single Dukes’ stage. The patients in
this study all had uniform treatment with no post-operative radio-
or chemotherapy and follow-up was for between 5 and 10 years.
High tumour levels of plasminogen activator inhibitor-2 (PAI-2) in
Dukes’ B (n = 82) and C (n = 54) colorectal cancers has also been
found to be prognostically significant (P = 0.05), but not indepen-
dent of Dukes’ stage, in a group of 136 colorectal cancers (Ganesh
et al, 1997).
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CD44 is a cell-surface glycoprotein which functions as an adhesion
molecule. Multiple isoforms of CD44 are generated by alternative
splicing of up to ten exons that encode for the molecule’s extracel-
lular portion. CD44 variants have been identified on the surface of a
variety of tumour cells. CD44v6 was studied by immunohistochem-
istry in a series of colon cancers (n = 68) with follow-up of between
6.5 and 9.5 years (Mulder et al, 1994). The report did not indicate
the distribution of tumours in different Dukes’ stages or the post-
operative treatments received by the patients. Tumours that strongly
expressed CD44v6 had a poorer prognosis than those tumours that
showed less intense or no immunostaining. This was stated to be
independent of Dukes’ stage. CD44 exons 8–10 was studied using
immunohistochemistry in 215 colorectal tumours (stage I, 37; II, 71;
III, 85; IV, 22) (Yamaguchi et al, 1996). There was no significant
immunoreactivity for CD44 in normal mucosa while there was
positive immunoreactivity in tumour cells. Immunoreactivity was
assessed as either present or absent, although the cut-off point for
negative score was less than 25% of tumour cells. The presence of
CD44 was associated with poorer prognosis, and in multivariate
analysis this factor remained independently prognostic.
E-cadherin
E-cadherin is a member of the cadherin family of calcium-depen-
dent adhesion molecules that function as mediators of cell-to-cell
adhesion. It is a transmembrane protein with a large extracellular
domain and a smaller cytoplasmic component which interacts with
cytoplasmic proteins, particularly b-catenin. Loss of E-cadherin is
associated with increased cell invasiveness. E-cadherin was studied
by in situ hybridization in 49 Dukes’ B colorectal cancers (Dorudi et
al, 1995). In situ hybridization was performed because antibodies
which reliably detect E-cadherin in formalin-fixed, wax-embedded
sections do not appear to be currently available. The lowest expres-
sion of E-cadherin was associated with poor survival. In a second
study, E-cadherin expression was investigated by in situ hybridiza-
tion in 32 colorectal cancers (Dukes’ A, B and D). None of the
patients had received chemotherapy and all had been followed up
for at least 5 years (Kitadai et al, 1996). The profile of expression of
E-cadherin was also compared with several other genes involved in
tumour invasion, including type IV collagenase. There was no prog-
nostic significance of E-cadherin expression, although low levels of
E-cadherin and a high ratio of type IV collagenase to E-cadherin
were associated with an increased incidence of metastasis.
Helix pomatia agglutinin
Helix pomatia agglutinin (HPA) is a sugar-binding protein, or
lectin, which binds specifically to N-acetylgalactosamine residues.
The binding of this lectin has been suggested to be of prognostic
significance in breast cancer. HPA binding was studied in 130
colorectal cancers (Dukes’ stage A, 14; B, 49; C, 62; unknown, 5).
Using a histochemical approach to detect binding of this lectin
(Schumacher et al, 1994). HPA binding correlated with Dukes’
stage, but was not independently prognostic.
INTRACELLULAR TARGETS OF
CHEMOTHERAPY
Thymidylate synthase
Thymidylate synthase (TS) is the primary intracellular target for
two of the more commonly used chemotherapeutic agents for
colorectal cancer, 5-FU and raltitrexed (tomudex). Elevated
expression of the TS protein has been demonstrated in cell lines
which were made resistant to either 5-FU or tomudex (Johnston et
al, 1992; Jackman et al, 1995). A higher degree of tumour TS
mRNA and protein was observed in patients with a poor response
to 5-FU in a small study of colorectal (n = 9) and gastric (n = 12)
cancers (Johnston et al, 1995). TS mRNA expression provided a
clearer definition of patient response than did protein level in this
study. Quantitative PCR assay of TS mRNA was then applied to
tumour tissue from 46 patients with advanced colorectal cancer
receiving protracted infusion of 5-FU (200 mg m–2 per day for 21
days) and weekly leucovorin (Leichman et al, 1997). No patient
with a ratio of TS to b-actin (used as an intertumour control)
greater than 4.1 ´ 10–3 responded. Using the median TS/b-actin
ratio as a cut-off point, survival was significantly higher (median
13.6 months) in patients with less than median TS levels than in
those with greater than median values (8.2 months) (Leichman et
al, 1997). Similar results have recently been reported in patients
receiving hepatic artery infusion of fluoropyrimidines, when
patients with low TS mRNA expression were 4.1-fold more likely
to respond to chemotherapy (Kornmann et al, 1997). TS anti-
bodies, which work on formalin-fixed, paraffin-embedded tumour
tissue, have provided the opportunity for retrospective analysis of
the prognostic significance of TS staining in patients with
colorectal cancer. TS was assessed with a semiquantitative visual
grading system based on the intensity of staining (0 to +++) and
extent of staining (focal, <25% positive cells; diffuse, >25% posi-
tive cells) (Johnston et al, 1994). An initial study in 294 patients
(Dukes’ stage A, 32; B, 92; C, 146; D, 24) from NSABP study R-
01 demonstrated that high expression of TS protein in tumour is
associated with a poor survival rate in patients receiving 5-FU-
based adjuvant chemotherapy for rectal cancer (Johnston et al,
1994). TS staining intensity was an independent prognostic
marker and identified a significant impact of 5-FU-based
chemotherapy in patients with high TS levels. However, TS
staining did not predict disease response among 134 patients
receiving 5-FU-based chemotherapy for advanced colorectal
cancer (Findlay et al, 1997). A significant time interval between
surgical resection of the primary tumour and treatment of
advanced disease was observed for most patients. As this study
performed TS staining on the primary tumour only, this may point
to clinically significant differences between TS staining in primary
and metastatic tumour. Although TS staining has demonstrated
potential prognostic significance, prospective studies are required
to confirm the importance in adjuvant chemotherapy and to deter-
mine the role of TS levels in advanced colorectal cancer.
GENERAL MARKERS
Carcinoembryonic antigen
Carcinoembryonic antigen is often used as a serum marker in
follow-up studies of colorectal cancer to detect recurrences/
metastasis. However, generally, the detection of CEA staining in
colorectal tumour samples has not been found to be useful in
providing prognostic information.
Sialyl Lewisx antigen
The sialyl Lewis antigen (sLex) is a cell-surface glycoprotein which
is part of the blood group system of antigens and may serve as
a ligand for endothelial leucocyte adhesion molecule. This may
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step in the metastatic cascade. High expression of this antigen is
associated with increased tumour cell invasion. The presence of
sLex in 132 colorectal cancers (stage I, 36; II, 40; III, 38; IV, 18)
was evaluated by immunohistochemistry on formalin-fixed, wax-
embedded sections with a monoclonal antibody to this antigen
(Nakamori et al, 1993). Tumours with greater than 5% of positive
cells were assessed as positive and those with less than 5% positive
cells were scored as negative. Follow-up was between 5 and 7
years. The presence of the sLex was associated with depth of
tumour invasion, lymphatic invasion, lymph node metastasis and
tumour stage. Overall and disease-free 5-year survival was signifi-
cantly less in the sLex-positive tumours, and this factor was also
independently prognostic for both overall survival and disease-free
survival.
CONCLUSIONS
Although the difficulty in identifying markers of prognosis has led
to much scepticism, there is still a real need for methodologies to
guide the choice of therapy and use health care expenditure in a
more rational manner for this common disease. Future studies
must focus on multiple markers in large numbers of patients at a
single disease stage in order to provide definitive evidence on the
clinical utility of prognostic markers and their relative contribution
to the prediction of survival. The recent emphasis by the National
Cancer Institute on pathology archives linked to large therapeutic
studies as a resource for collaborative research is an example of
the way funding can be used to answer these important questions
about patient care.
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